Want to see CTNM full AI Analyst Report?
CTNM Stock Chart & Stats
$13.53
-$0.71(-5.12%)
At close: 4:00 PM EST
$13.53
-$0.71(-5.12%)
Day’s Range― - ―
52-Week Range$4.67 - $16.91
Previous CloseN/A
Volume54.82K
Average Volume (3M)170.88K
Market Cap
$532.01M
Enterprise Value$441.41M
Total Cash (Recent Filing)$246.33M
Total Debt (Recent Filing)$6.95M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 18, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding32,723,877
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.59K
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$21.20Price Target Upside56.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$8.26M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low leverage and sizable equity provide durable financial flexibility to fund multi-year clinical development and absorb trial setbacks. This reduces immediate liquidity pressure, lowers the urgency of dilutive financing, and supports strategic partnerships and R&D investments over an extended development horizon.
Positive Phase 1b Data For PIPE-791Favorable safety/tolerability and exploratory efficacy signals in the Phase 1b chronic pain trial materially de-risk PIPE-791 versus preclinical candidates. Durable program de-risking increases the probability of advancing to larger studies, attracting partners, and justifying prioritized resource allocation over the medium term.
Clear Strategic Focus And Stated Cash RunwayConcentrating resources on PIPE-791 while deferring other programs reflects capital discipline and clearer development priorities. Publishing an expected cash runway through mid-2029 gives a multi-year planning horizon, reducing near-term execution risk and enabling measured partnership or milestone planning.
Bears Say
Zero Recent RevenueAbsence of recurring product revenue means the company cannot self-fund development from operations. Over the medium term this increases dependency on equity or partnership financing, heightens dilution risk for shareholders, and limits internal flexibility to expand or accelerate programs.
Sustained Cash BurnPersistent negative operating and free cash flow at materially negative TTM levels signals ongoing funding needs. Even with low leverage, sustained burn will force financing events or partner deals that can constrain strategy, dilute equity, or delay programs if market conditions shift.
Pipeline Concentration And Partnership RelianceHeavy emphasis on a single lead asset and deferral of other programs increases binary outcome risk: setbacks to PIPE-791 would have outsized impact. Reliance on external partners for other assets reduces control over development timelines and outcomes, and constrains diversification of future revenue sources.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $4.67 and its highest was $16.91 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $532.01M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Aug 18, 2026 which is in 27 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on May 05, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.532 by $0.142.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.45.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 32,723,877 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.532. Following the earnings report the stock price went up 3.822%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Contineum Therapeutics, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.20 (56.69% Upside)
$21.20 (56.69% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
31.82%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
CTNM Stock 12 Month Forecast
Average Price Target
$21.20
▲(56.69% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.52% Insiders
8.98% Mutual Funds
<0.01% Other Institutional Investors
81.50% Public Companies and
Individual Investors